David Steensma: IND application for first type II JAK2 inhibitor to go into clinical trials

David Steensma, Chief Medical Officer at Ajax Therapeutics, shared a post by Ajax Therapeutics on X/Twitter:

“We’ve been busy at Ajax Therapeutics! IND application for first type II JAK2 inhibitor (AJ1-11095) to go into clinical trials, based on pre-clinical work done  at Ross Levine lab and with a molecule designed in collaboration with Schrödinger Therapeutics, has been cleared by U.S. FDA.

Here’s the listing for the first-in-human AJ1-11095 study (NCT06343805) for patients with myelofibrosis who’ve previously been treated with a type I JAK2 inhibitor but still have symptoms and an enlarged spleen.”

Quoting Ajax Therapeutics’s post:

“Ajax Announcement #2. The IND for our lead molecule, AJ-101095, a potent selective type II JAK inhibitor, has been cleared by the FDA. Next stop->clinic. Let’s go!.”

Source: David Steensma/X and Ajax Therapeutics/X